文献速递艾滋病与性传播感染

Fostemsavir降低重经治疗HIV感染者抗gp120 CD4诱导抗体水平

Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV.
PubMed 文献 · J Infect Dis · 2026-01-01

本研究基于BRIGHTE试验和PRESTIGIO登记,检测重经治疗HIV感染者接受fostemsavir治疗前后血浆抗gp120 CD4诱导抗体水平,并与SAILING试验对照比较。结果显示两个fostemsavir治疗组该抗体显著下降而对照组无变化,且该下降与血浆识别清除gp120包被的未感染CD4+ T细胞能力降低相关。

要点

  • Fostemsavir治疗可显著降低重经治疗HIV感染者抗gp120 CD4诱导抗体水平。
  • 该抗体下降伴随血浆清除gp120包被未感染CD4+ T细胞能力降低。
  • Fostemsavir可能通过减少CD4诱导抗体提供额外免疫获益。

核心结论

  • Fostemsavir可能通过降低抗gp120 CD4诱导抗体水平,在阻断病毒进入之外为HIV感染者提供额外免疫获益。

研究设计与样本

  • 研究检测BRIGHTE试验和PRESTIGIO登记中重经治疗HIV感染者fostemsavir治疗前后血浆抗gp120 CD4诱导抗体水平,并与SAILING试验对照ART治疗组比较。

主要发现

  • 两个fostemsavir治疗的重经治疗组抗gp120 CD4诱导抗体均显著下降,对照组无显著变化。
  • 靶向Gag的抗体水平无显著变化,提示该效应为抗gp120 CD4诱导抗体所特有。
  • 抗gp120 CD4诱导抗体下降与血浆识别和清除包被可溶性gp120的未感染原代CD4+ T细胞能力降低相关。

临床怎么用

  • 在重经治疗HIV感染者中,fostemsavir治疗可能降低抗gp120 CD4诱导抗体并减少其介导的CD4+ T细胞清除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heavily treatment-experienced (HTE) people with HIV (PWH) have limited antiretroviral therapy (ART) treatment options, putting them at greater risk of unfavorable human immunodeficiency virus 1 (HIV-1) disease progression. Fostemsavir (BMS-663068) efficiently suppressed viremia and increased CD4 count when combined with other antiretrovirals in HTE PWH. Its active metabolite, temsavir (BMS-626529, GSK2616713), binds a conserved pocket within the envelope glycoprotein (Env) CD4 binding site and prevents CD4-induced conformational changes. Temsavir effect on Env conformation profoundly alters its glycosylation and cleavage, thereby modifying its antigenicity and reducing gp120 shedding. Here we evaluated if fostemsavir treatment in PWH modulated the levels of nonneutralizing gp120 CD4-induced (CD4i) antibodies (Abs) associated with CD4 depletion in vitro and in PWH. METHODS: We measured the levels of anti-gp120 CD4i Abs in plasma samples taken before and after fostemsavir treatment in HTE participants from the BRIGHTE trial and the PRESTIGIO registry and compared them to those of a control ART-treated group from the SAILING trial. RESULTS: We observed a significant decline of anti-gp120 CD4i Abs in the 2 fostemsavir-treated HTE groups, but not in the control group. Moreover, this effect was unique to anti-gp120 CD4i Abs, as no significant changes were observed in the levels of antibodies targeting Gag. Functionally, this decline in CD4i Abs was associated with a reduced capacity of plasma to recognize and eliminate uninfected primary CD4+ T cells coated with soluble gp120. CONCLUSIONS: Altogether, fostemsavir may provide additional immune benefits to PWH, beyond blocking viral entry, by reducing anti-gp120 CD4i Abs levels. CLINICAL TRIALS REGISTRATION: NCT04098315, NCT01231516, and NCT02362503.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Benlarbi M, Richard J, Clemente T, et al. Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV. J Infect Dis. 2026. PMID: 40990223. doi:10.1093/infdis/jiaf461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。